Use of antisecretory factors (AF) for optimizing cellular uptake

• US 9,962,424 B2
• Filed: 10/15/2015
• Issued: 05/08/2018
• Est. Priority Date: 04/27/2007
• Status: Active Grant

• Current Assignee: Lantmannen AS-Faktor AB (Lantmannen ek for)
• Original Assignee: Lantmannen AS-Faktor AB (Lantmannen ek for)
• Inventors: Jennische, Eva, Lange, Stefan, Hansson, Hans-Arne
• Primary Examiner(s): Gudibande, Satyanarayana R
• Assistant Examiner(s): Lee, Jia-Hai
• Application Number:
  US14/883,734
• Publication Number:
  US 20160030515A1
• Time in Patent Office: 936 Days
• Field of Search: None
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 35/57 Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07K 7/04 Linear peptides containing only normal peptide links
• CPC Class Codes: G01N 2333/912 transferring phosphorus containing groups, e.g. kinases (2.7)
• CPC Class Codes: G01N 2500/10 involving cells

Abstract

The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.

Claims

1. A composition comprising the amino acid sequence consisting of SEQ ID NO:

4 or a pharmaceutically acceptable salt thereof in combination with a non-peptidic low molecular weight drug which is cytotoxic or cytostatic.

2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier or excipient.

3. The composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is selected from the group consisting of a solvent, a buffering agent, a preservative, a chelating agent, an antioxidant, a stabilizer, an emulsifying agent, a suspending agent, a diluent, and a disintegrating agent.

4. The composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient comprises microspheres or liposomes.

5. The composition of claim 3, wherein the solvent is selected from the group consisting of water, alcohol, blood, plasma, spinal fluid, ascites fluid, and lymph fluid.

6. The composition of claim 3, wherein the buffering agent is selected from the group consisting of citric acid, acetic acid, tartaric acid, lactic acid, hydrogen phosphoric acid, bicarbonates, phosphates, and diethylamide.

7. The composition of claim 3, wherein the chelating agent is EDTA or citric acid.

8. The composition of claim 3, wherein the antioxidant is selected from the group consisting of butylated hydroxyl anisole (BHA), ascorbic acid and derivatives thereof, tocopherol and derivatives thereof, cysteine, and mixtures thereof.

9. The composition of claim 3, wherein the diluent or disintegrating agent is selected from the group consisting of lactose, saccharose, emdex, calcium phosphates, calcium carbonate, calcium sulphate, mannitol, starches, and microcrystalline cellulose.

10. The composition of claim 3, wherein the binding agent is selected from the group consisting of saccharose, sorbitol, gum acacia, sodium alginate, gelatin, chitosan, starches cellulose, carboxymethylcellulose, methylcellulose, hydroxyproplycellulose, polyvinylpyrrolidone, and polyethylene glycol.